Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches

The top concern for Bayer’s pharma business is the looming patent cliff for its two best-sellers—blood thinner Xalreto and eye drug Eylea. The blockbuster meds will leave a revenue gap that the company’s pipeline program won’t be able to fill in the next few years.